Results 111 to 120 of about 222,938 (359)

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood [PDF]

open access: yes, 1973
The hepatotrophic factors previously reported to be in splanchnic venous blood are pancreatic hormones and specifically insulin and glucagon. Of these, insulin is anabolic and glucagon is mainly catabolic but not exclusively so, since glucagon also has ...
Brown, TH   +6 more
core  

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Completeness of spontaneously reported adverse drug reactions in 4 databases

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To assess the completeness of information provided in adverse drug reaction (ADR) reports in 4 spontaneous report databases. Methods The study was conducted using freely accessible ADR reports from the Canada Vigilance Adverse Reaction Online Database, the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, the UK ...
Mohammed Gebre Dedefo   +5 more
wiley   +1 more source

Glucagon and insulin immunopositivity of mast cells in porcine gallbladder

open access: yesBulgarian Journal of Veterinary Medicine
It is well known that mast cells produce and release biologically active substances such as histamine, heparin, proteases, leukotrienes, cytokines, chemokines and growth factors. According to the avail-able scientific literature on that topic this is the
I. Stefanov, S. Stefanov, M. Gulubova
doaj   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman   +13 more
wiley   +1 more source

THE INTERACTION OF GLUCAGON AND INSULIN ON BLOOD GLUCOSE [PDF]

open access: bronze, 1956
Harold Elrick   +3 more
openalex   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee   +5 more
wiley   +1 more source

Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]

open access: yes, 2019
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S   +16 more
core   +1 more source

Effect of Insulin and Glucagon on Tumour Growth [PDF]

open access: green, 1958
James Salter, Roland Meyer, C. H. Best
openalex   +1 more source

Home - About - Disclaimer - Privacy